Vir Biotechnology Announced New Preliminary Data From Phase 2 SOLSTICE Hepatitis Delta Trial, Showing Tobevibart Alone Or Combined With Elebsiran Was Generally Well Tolerated And Patients Achieved High Virologic Response And ALT Normalization
Vir Biotechnology Announced New Preliminary Data From Phase 2 SOLSTICE Hepatitis Delta Trial, Showing Tobevibart Alone Or Combined With Elebsiran Was Generally Well Tolerated And Patients Achieved High Virologic Response And ALT Normalization
Vir Biotechnology宣佈來自第2期SOLSTICE肝炎Δ試驗的新初步數據，顯示Tobevibart單獨或與Elebsiran結合治療通常耐受良好，患者達到高病毒學反應和ALT正常化。
Vir Biotechnology Announced New Preliminary Data From Phase 2 SOLSTICE Hepatitis Delta Trial, Showing Tobevibart Alone Or Combined With Elebsiran Was Generally Well Tolerated And Patients Achieved High Virologic Response And ALT Normalization
Vir生物技術公司宣佈來自第二期SOLSTICE Hepatitis Delta臨床試驗的新初步數據，顯示Tobevibart單獨或與Elebsiran聯合使用通常耐受良好，並且患者取得了高病毒學反應和ALT指標正常化。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。